AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$2.55 USD
-0.01 (-0.39%)
Updated Jul 31, 2024 04:00 PM ET
4-Sell of 5 4
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ANTX 2.55 -0.01(-0.39%)
Will ANTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANTX
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
Other News for ANTX
Strong Buy on AN2 Therapeutics: Anticipating Positive Phase 2 Outcomes and Robust Financial Position
12 Health Care Stocks Moving In Friday's After-Market Session
Maintain Market Perform: Balancing Potential and Uncertainty in AN2 Therapeutics’ Drug Development
AN2 Therapeutics price target lowered by $5 at Evercore ISI, here's why
AN2 Therapeutics reports Q1 results